

December 18, 2020

Announcements

Francesca Montanari, MD Providing Hematology Expertise in Greenwich

Dr. Francesca Montanari has joined the Smilow Cancer Hospital Care Center at Greenwich as an Assistant Professor of Clinical Medicine (Hematology) and cares for patients with hematologic malignancies. Dr. Montanari joined Yale Cancer Center from New York Presbyterian Hospital – Columbia University Medical Center, College of Physicians and Surgeons where she was Assistant Professor of Medicine & Experimental Therapeutics in the Department of Medicine, Division of Experimental Therapeutics.



Dr. Montanari received her medical degree from the University of Pavia in Italy where she graduated magna cum laude and completed both her residency and fellowship at New York University School of Medicine, where she was awarded the Fellow of the Year teaching award. She currently has several research studies focused on relapsed/refractory hematologic and lymphoid malignancies.

Holiday Cheer!

A highlight of our month was the Yale Cancer Center and Smilow Cancer Hospital holiday party last week. While we were not able to celebrate in grand style together at the Peabody Museum as in past years, we did gather virtually and share messages of hope, strength, and cheer, along with music and other fun surprises. Thank you to Dean Nancy Brown and Marna Borgstrom for joining us and to the many members of our faculty and staff who sent messages to our teams. If you missed the event, you can watch [online](#).

In Memoriam: Linda Mowad, RN

It is with great sadness that we share the news of the passing of Linda Mowad, RN, former director of Yale Cancer Center's Cancer

from the desk of

Charles S. Fuchs, MD, MPH
Director, Yale Cancer Center
and Physician-in-Chief
Smilow Cancer Hospital



Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale **CANCER**
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

News Center

Pandemic Depression: an action plan



[Read More](#)

**YCC Members Take Home Top Awards at Yale
Lifesciences PitchFest 2020**

Information Service Office, and our inaugural institutional representative to the Connecticut Cancer Partnership. Linda launched Yale's Cancer Information Service (CIS) office on behalf of the National Cancer Institute in 1976 and continued to lead the Service through many technology transitions, innovations, and partnerships until her retirement 35 years later. Through her dedicated career and volunteer positions in the cancer prevention and control arena, Linda's contributions will be felt in Connecticut long into the future. Please keep Linda's family in your thoughts and prayers as they mourn their beloved mother and grandmother.

Closer to Free Fund Matching Gift Challenge

A Matching Gift Challenge for friends of Smilow Cancer Hospital and Yale Cancer Center has been established by All American Waste, a local, family-owned business that is invested in the cancer care and research that we do. Giving back to the community has always been a core value of All American Waste's ownership and they are excited to offer this matching challenge for others in the community to help give patients a better chance to beat their cancer. Any gift you make between now and December 31st to the Closer to Free Fund will be matched dollar-for-dollar – up to \$25,000 – by All American Waste.

[Learn More](#)

iLab Launches

YCC's Office of Research Affairs is excited to announce that iLab, a web-based, core facility management platform used by over 200 research institutions worldwide, is now available to the YCC community through our Rapid Case Ascertainment, Yale Center for Precision Cancer Modeling, and Biostatistics Shared Resources. The program launched on December 14th and Yale Cancer Center members have automatically been entered into the iLab system and can begin using it to request services or schedule equipment usage from these shared resources. More information is available on the [YCC iLab website](#). Please contact [Joseph Salemme](#) with questions.

Notables

Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the **2020 Clinical Research Award** recipient by the **Association of Community Cancer Centers (ACCC)** for significantly and positively impacting oncology patients, their families, and the broader oncology community. The ACCC is one of the largest education and advocacy organizations for the cancer care community. [Learn More](#)

Marcella Nunez-Smith, MD, MHS, a co-chair of President-elect Biden's COVID-19 advisory board, will also lead a new White House task force dedicated to health equity. At Yale Cancer Center and Smilow Cancer Hospital, Dr. Nunez-Smith is Director of the Center for Community Engagement and Health Equity and Chief Health Equity

Officer & Deputy Chief Medical Officer at Smilow Cancer Hospital, and Associate Cancer Center Director for Community Outreach and

YALE LIFESCIENCES PITCHFEST

[Read More](#)

Gene Expression Testing Varies Substantially by Region for Prostate Cancer




[Read More](#)

New Immunotherapy Treatment for Lung Cancer



[Watch Now](#)

Yale Cancer Center Study Shows Caplacizumab Not Cost Effective for Rare Blood Disorder



[Read More](#)



Engagement at Yale Cancer Center.

Sabrina Browning, MD, Instructor of Medicine (Hematology), has been selected as the recipient of Yale Cancer Center's **Forget Scholar** for 2020. The Forget Scholar award was established in 2015 through contributions of several individuals in honor of Dr. Bernard Forget, renowned hematologist and scientist who made pioneering contributions to the study of red cells, hemoglobin, and the genetics of blood disorders. The annual award is given to a deserving individual who is transitioning from their fellowship to an academic career in hematology by way of salary support.

Carrie Redlich, MD, MPH, Professor of Medicine (Occupational Medicine) and of Environmental Health Sciences, has received the **2020 Harriet Hardy Award** presented by New England College of Occupational and Environmental Medicine (NECOEM). Dr. Redlich gave her award lecture presentation on December 3 to the NECOEM annual conference. It was titled *The Changing Landscape of Work-related Lung Diseases*.

James Hansen, MD, Associate Professor of Therapeutic Radiology, was recently awarded two grants to support his research, including a **Breast Cancer Research Program Breakthrough Award** from the Department of Defense for use of a modified autoantibody against breast cancer brain metastases and a **NIH NINDS R01** grant for targeting glioblastoma with a nuclear-penetrating anti-DNA antibody.

Jean L. Bologna, MD, Professor of Dermatology, is one of six people who have been named 2020 Giants of Dermatology by *Dermatology Times*. The program recognizes leading physicians and researchers in the field of dermatology whose landmark successes, ongoing inspiration, and career-long dedication redefine what is possible for this specialty.


Congratulations to YCC members **Joseph Contessa, MD, PhD, Ranjit Bindra, MD, PhD, and W. Mark Saltzman, MD, PhD**, for receiving top cash awards at this year's **Yale Lifesciences PitchFest 2020**. Dr. Contessa received the award for Highest Potential Impact for his work in *Developing Therapeutic OST Inhibitors* and Drs. Bindra and Saltzman received the award for Most Innovative Breakthrough for their work in *Redefining the Blood-brain Barrier*. [Learn More](#)

NCCN News

The NCCN 2021 Virtual Congress: **Breast Cancer with Updates from the 2020 San Antonio Breast Cancer Symposium (SABCS)**, presented in partnership with Robert H. Lurie Comprehensive Cancer Center of Northwestern University, will provide expert insights on the current standard of care for patients with breast cancer. The Congress will also include the latest clinical research updates from the 2020 SABCS to assist clinicians in formulating breast cancer management strategies.

The event will take place on **Friday, February 12, 2021** from 10:30 AM

Join Smilow Cancer Hospital on Facebook




Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital wishes everyone Happy Holidays and thanks the Smilow team for their hard work and growth over the last 10 years of Smilow!



Watch Now

Learn about our Smilow Cancer Hospital Care Center in Westerly, RI, which offers leading edge technologies, resources, and expertise throughout Rhode Island and eastern Connecticut. Our Westerly location provides access to state-of-the-art radiation and surgical treatment, genetic testing, and clinical trials in partnership with Yale Cancer Center, along with a comprehensive suite of services.



Watch Now

Nina Kadan-Lottick, MD, MSPH, Associate Professor of Pediatrics (Hematology/Oncology), has been appointed to the Executive Committee of the NCI-funded Children's Oncology Group, which is responsible for strategic planning, resource allocation, performance monitoring, review of the Operations Office and the Statistics and Data Management Center. Thank you, Dr. Kadan-Lottick for your dedicated efforts on behalf of our littlest patients!

– 5:15 PM EST. Healthcare professionals from Member Institutions receive a discounted registration rate of \$25 with complimentary registration for fellows and residents. [Agenda Register](#)

Employee Profile: Kelly Ford

Kelly Ford is a Licensed Clinical Social Worker who works in Bereavement Support Services, a program under the Palliative Care Service, for families after a loved one has died, as well as patients undergoing radiation therapy at the Smilow Cancer Hospital Care Center at Hamden. While these patient populations are very different, Kelly takes a similar approach when working with them.




“I think it’s important to give both populations permission to honor and understand their feelings,” she says. “Normalizing feelings, whether it’s a grieving family member who is struggling with if it’s okay to enjoy a happy moment, or if it’s a patient just starting radiation, who is scared of the unknown. Validating their feelings and reassuring that their emotions are ‘normal’ is where I start.”

Kelly has worked with the outpatient population for the last five years after covering multiple areas in inpatient social work for nine years prior. Seeing the process and helping patients and their families successfully navigate the health system and secure a simple resource could mean the world to them.

Kelly provides consultations and psycho-social support for patients starting and undergoing radiation treatment in the Hamden Care Center, and she leads virtual bereavement support groups, grief seminars, and at this time of year, the Hope for the Holidays program, which helps families manage their grief through the holiday season.

“Offering support when someone needs it most – when they may or may not have support from family and friends, that’s what I enjoy every day,” says Kelly

#OUTOFTHEBLUETHANKS to Marion Miller!



Nina Kadan-Lottick, MD, MSPH, appointed to the Executive Committee of the NCI-funded Children’s Oncology Group



[Read More](#)

Dr. Melinda Irwin, Associate Director for Population Sciences at Yale Cancer Center, discusses her mini symposium talk and poster presentations at the San Antonio Breast Cancer Symposium this week #SABCS20 related to The Lifestyle, Exercise and Nutrition (LEAN) Study. Watch to learn more about her research on the connection between exercise, nutrition, and cancer.



[Watch Now](#)

Congratulations to Trisha Burrello, Diane Eannotti, Laura Leary, Neta Shanwetter Levit, Talia Mitchell, Kira Pavlik, and Sara Raboin from the Yale Cancer Center Clinical Trials Office who were awarded a Linda K. Lorimer Award for Distinguished Service this year in recognition of the work they did to rapidly transition Smilow cancer patients, researchers, and staff to remote care and work while upholding a high level of productivity, engagement, and quality.

Congratulations!



Yale Cancer Center & Smilow Cancer Hospital's #OUTOFTHEBLUETHANKS recently recognized Marion Miller, Administrative Assistant, for going above-and-beyond in her role during the recent pandemic. Under normal circumstances, Marion Miller is the "go-to person" for the Yale Cancer Center community and that has become even more apparent during the COVID-19 pandemic. On a normal day, Marion's job as Administrative Assistant for Yale Cancer Center exposes her to many different departments, and various tasks throughout the Center. During her over 20 years of service at the university, she has established many crucial relationships in departments such as Facilities, TR&S (Transport, Receiving, & Storage), Telecom, ITS, & Security, in addition to many external vendors like WB Mason and BBI Technologies, that were a vital part of how our department was able to successfully navigate and adapt during these challenging times. Marion is serving as a crucial lifeline for faculty and staff, spending a few hours a week on-site organizing and distributing incoming mail and other urgent deliveries, in addition to assisting with other mission critical projects that have come up—like coordinating renovation needs when a flood damaged multiple offices, to name one example. From the onset of the pandemic, Marion was directly involved in figuring out how we could adapt the processes behind our normal daily functions in order to keep them going. Thanks to Marion's efforts the Cancer Center faculty and staff have been able to keep vital operational needs moving forward even though the majority of our team is still working remotely. She is literally our anchor to the campus during a time when we all feel as if we are floating aimlessly into the unknown. She is the definition of a team player and always happy to help anyone, anywhere, in any way. Thank you, Marion!

Yale Cancer Center & Smilow Cancer Hospital's #OUTOFTHEBLUETHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. If you are interested in submitting a nomination, please complete this [nomination form](#) and return it to the Director's Office c/o **Anna Raso**.

Recent Publications


Sadras T, Chan LN, Xiao G, Mutschen M. (2020). **Metabolic Gatekeepers of Pathological B Cell Activation** *Annual Review of Pathology: Mechanisms of Disease*, Online ahead of print.





[Read More](#)


Follow Yale Cancer Center on Twitter


Follow us on [twitter](#)


 Tune in today at Noon for @YaleCancer Grand Rounds. Dr. Nikolai Podoltsev will discuss #PolycythemiaVera and Dr. Thomas Prebet will present "Overcoming Hypomethylating Agent Failure in #AML and #MDS."

 Congratulations to @DrRoyHerbstYale for receiving the @ACCCBuzz 2020 Clinical Research Award for his work in advancing #lungcancer treatment and care. @SmilowCancer @YaleMed @YNHH #lscm Roy S. Herbst, MD, PhD, Receives 2020 ACCC Clinical Research Award < Yale Cancer Center

 In an interview with @OncoLive, @MSzno1 discusses the importance of being aware of immune-related toxicities while treating #cancer patients.

 Tune in to the Best of @ASCO Africa 2020 virtual meeting today. @DrRoyHerbstYale will present #LungCancer advances from #ASCO20 to help improve care for #cancer patients in Africa.

 @BarbaraBurtress provided commentary in @practiceupdate on one of the 2020 Top Stories in Oncology "Transoral Surgery for #HPV-Associated Oropharynx Cancer."

 New research led by Dr. Mariya Rozenblit

and Dr. Lajos Pusztai at #SABCS20 reports on the "Comparison of PD-L1 Protein Expression Between Primary Tumors and Metastatic Lesions in Triple Negative #BreastCancers #TNBC."

Read More

Shapiro GI, LoRusso P, Dowlati A, T Do K, Jacobson CA, Vaishampayan U, Weise A, Caimi PF, Eder JP, French CA, Labriola-Tompkins E, Boisserie F, Pierceall WE, Zhi J, Passe S, DeMario M, Kornacker M, Armand P. (2020).

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.

British Journal of Cancer, Online ahead of print.

Read More

Chhoda A, Yousaf MN, Madhani K, Aslanian H, Jamidar PA, Suarez AL, Salem RA, Muniraj T, Kunstman J, Farrell JJ. (2020).

Comorbidities Drive the Majority of Overall Mortality in Low-risk Mucinous Pancreatic Cysts under Surveillance

Clinical Gastroenterology and Hepatology, Online ahead of print.

Read More

Das A, Mahapatra S, Bandyopadhyay D, Samanta S, Chakraborty S, Philpotts LL, Jahangir E, Roy B. (2020).

Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.

Critical Reviews in Oncology/Hematology, Online ahead of print.

Read More

Sznol M, Melero I. (2020)

Revisiting Anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy.

Annals of Oncology, Online ahead of print.

Read More

Aslam, A., Do, R., Kambadakone, A., Spieler, B., Miller, F. H., Gabr, A. M., Charalel, R. A., Kim, C. Y., Madoff, D. C., & Mendiratta-Lala, M. (2020).

Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions.

World journal of hepatology, 12(10), 738–753.

Read More

Prozora S, Shabanova V, Ananth P, Pashankar F, Kupfer GM, Massaro SA, Davidoff AJ. (2020)

Patterns of medication use at end of life by pediatric inpatients with cancer.

Pediatric Blood & Cancer, Online ahead of print.

Read More

Grinman D, Athonvarungkul D, Wysolmerski J, Jeong J. (2020).

Calcium Metabolism and Breast Cancer: Echoes of Lactation?

Current Opinion in Endocrine and Metabolic Research

Read More

Toki MI, Syrigos N, Syrigos K. (2020).

Hyperprogressive disease: A distinct pattern of progression to



Thanks to clinical trials @YaleCancer , research at #SABCS20 led by Dr. Lajos Pusztai finds some postmenopausal women w/early stage #breastcancer can skip #chemotherapy & receive only hormonal therapy. @SmilowCancer @YaleMed @YNHH RxPONDER Results Announced at 2020 SABCS | SWOG



Dr. David Rimm .@RimmPathology reports on new research at #SABCS20 Comparing Pathologist Reads of sp142 and sp263 with Quantitative Measurement of Protein and mRNA in Triple Negative #BreastCancer #TNBC.



New research led by @SMougalian at #SABCS20 shows the "Effectiveness of Eribulin in Poor Prognosis Subgroups of Metastatic #BreastCancer patients in the U.S."



.@mirwin_yale discusses her mini symposium talk and poster presentations at virtual #SABCS20 related to The Lifestyle, Exercise and Nutrition (LEAN) Study.



Join us at Noon today for @YaleCancer virtual Grand Rounds. @DavidHaflerMD discusses "Co-inhibitory Receptors on Human T Cells" and Dr. Harriet Kluger discusses "Co-Stimulating Innate & Adaptive Immunity to Treat #Melanoma."



Virtual #SABCS20 starts today! Our @YaleCancer @SmilowCancer team including Dr. Lajos Pusztai, @mirwin_yale @tarasanftmd & @SMougalian will present the latest in #breastcancer advances alongside researchers and clinicians from around the world.



New research led by Dr. Rong Wang, @Dr_RoryShallis & Nikolai Podoltsev presented today @ASH20 reports on "Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with #ChronicMyeloidLeukemia in the U.S."



"We've opened up another treatment option for patients with this rare disease." — @Terri_ParkerMD on @YaleCancer led @SWOG study presented @ASH20 showing encouraging

news for patients with #ALamyloidosis .

Calendar

Typical progressive disease with distinct pattern of progression to

immune checkpoint inhibitors.

International Journal of Cancer, Online ahead of print.

Read More

Sheehan K, Price C, Hafez N. (2020).

Optimizing Care for Patients With Adverse Events From Immunotherapeutics.

Cancer Journal, 537-542.

Read More

Newton BR, Chiang AC. (2020)

Harnessing the Immune System to Tackle Small Cell Lung Cancer.

Cancer Journal, 26(6):502-506.

Read More

Sanmamed MF, Eguren-Santamaria I, Schalper KA. (2020)

Overview of Lung Cancer Immunotherapy.

Cancer Journal, 26(6):473-484.

Read More

Goldberg SB, Herbst RS. (2020)

Introduction by the Guest Editors.

Cancer Journal, 26(6):471-472.

Read More

Alvarado-Cruz I, Mahmoud M, Khan M, Zhao S, Oeck S, Meas R, Clairmont K, Quintana V, Zhu Y, Porciuncula A, Wyatt H, Ma S, Shyr Y, Kong Y, LoRusso PM, Lavery D, Nagel ZD, Schalper KA, Krauthammer M, Sweasy JB. (2020)

Differential immunomodulatory Effect of PARP Inhibition in BRCA1 deficient and competent tumor cells.

Biochemical Pharmacology, 114359.

Read More

Gupte TP, Li C, Jin L, Yalcin K, Youngblood MW, Miyagishima DF, Mishra-Gorur K, Zhao AY, Antonios J, Huttner A, McGuone D, Blondin NA, Contessa JN, Zhang Y, Fulbright RK, Gunel M, Erson-Omay Z, Moliterno J. (2020)

Clinical and genomic factors associated with seizures in meningiomas
Journal of Neurosurgery, 1-10.

Read More

Shallis RM, Pollyea DA, Zeidan AM. (2020)

Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials.

Lancet Haematology, (12):853-856.

Read More

D'Addario J. (2020)

Cervical cancer.

Journal of the American Academy of Physician Assistants, 33(12):51-52.

Read More

OBGYN Presents RSSP

December 18; 3:00 PM

Individual-oocyte Transcriptomic Analysis Shows that Genotoxic Chemotherapy Depletes Human Primordial Follicle Reserve by Triggering Proapoptotic Pathways Without Growth Activation
Katarzyna S-V, PhD

Learn More

Yale Cancer Answers

December 20; 7:30 PM

NPR

Benefits of Support Groups during the Holidays
Mary Strauss, LCSW

Learn More

ATS Thoracic Oncology Journal Club

December 21; 12:00 PM

Oligometastatic NSCLC

Learn More

Yale Pancreatic Cancer Collaborative Seminar Series

December 21; 2:00 PM

Reducing Mortality for What Will Be the #3 Cause of Cancer Death Two Years from Now
Harvey Risch, MD, PhD

Learn More

Genetics Clinical Grand Rounds

December 22; 10:15 AM

Laboratory Reevaluation and Reanalysis and Patient Re-contact for Cytogenetic VUS Findings
Peining Li, PhD

Learn More

Yale Cancer Answers

December 27; 7:30 PM

NPR

New Years Resolutions for Cancer Survivors during COVID-19

Maura Harrigan, MS, RDN, CSO

Learn More

Yale Cancer Answers

January 3; 7:30 PM

NPR

Menopause and Cancer

Mary Jane Minkin, MD

Learn More

Pathology Research in Progress Talk

January 5; 9:30 AM

Shalin Kothari, MD and Christopher Minter

Learn More

[Read More](#)

Yumeen S, Mirza FN, Lewis JM, Girardi M. (2020)

Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology.

Journal of Investigative Dermatology, 140(12):2319-2325.e1.

[Read More](#)

Muppidi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, Tavee JO, Kaminski H, Howard JF Jr, Cutter G, Wiendl H, Maas MB, Illa I, Mantegazza R, Murai H, Utsugisawa K, Nowak RJ; CARE-MG Study Group. (2020)

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG).

Lancet Neurology, 19(12):970-971.

[Read More](#)

Liu Y, Yang M, Deng Y, Su G, Enniful A, Guo CC, Tebaldi T, Zhang D, Kim D, Bai Z, Norris E, Pan A, Li J, Xiao Y, Halene S, Fan R. (2020)

High-Spatial-Resolution Multi-Omics Sequencing via Deterministic Barcoding in Tissue.

Cell, 183(6):1665-1681.e18.

[Read More](#)

Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V 3rd. (2020)

Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma.

Journal of Acquired Immune Deficiency Syndrome, 85(5):530-534.

[Read More](#)

Kaps B, Leapman M, An Y. (2020)

Trends in prostatectomy utilization: Increasing upfront prostatectomy and postprostatectomy radiotherapy for high-risk prostate cancer.

Cancer Medicine, (23):8754-8764.

[Read More](#)

Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leigh N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. (2020)

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.

Lancet Oncology, 21(12):1589-1601.

[Read More](#)

Lee YH, Lee JY, Lawson W. (2020)

Indications and Outcomes of the Osteoplastic Flap Procedure With or Without Obliteration.

Journal of Craniofacial Surgery, 31(8):2243-2249.

[Read More](#)

[Learn More](#)

Yale Cancer Center Grand Rounds/Frisbee Lecture

January 5; 12:00 PM

Mechanisms of B-cell Selection as Therapeutic Targets

Markus Müschen, MD, PhD

[Learn More](#)

Yale Center for Immuno-Oncology Seminar Series

January 5; 4:00 PM

TBD

Lisa Butterfield, PhD

[Learn More](#)

Intersections Science Fellows Symposium

January 6-8; All Day

Nancy J. Brown, MD | Darin Lattimore, MD | Gary Hunnicutt | Joan Steitz, PhD | Martha Munoz | Antonio Giraldez, PhD | Daniel Alfonso Colon-Ramos, PhD | Monkol Lek, PhD | Holden Thorp | Kizzmekia Corbett | Kafui Dzirasa

[Learn More](#)

Pathology Grand Rounds

January 7; 12:30 PM

TBD

Todd McDevitt, PhD

[Learn More](#)

Cancer Genetics and Prevention Seminar

January 7; 2:30 PM

TBD

[Learn More](#)

Neurology Clinical Grand Rounds

January 8; 12:00 PM

TBD

[Learn More](#)

Submissions

Please submit your recent publications, awards, and grant announcements to:

[Renee Gaudette](#)

Director, Public Affairs and Communications

Boffa DJ, Judson BL, Billingsley KG, Del Rossi E, Hindinger K, Walters S, Ermer T, Ratner E, Mitchell MR, Laurans MS, Johnson DC, Yoo PS, Morton JM, Zurich HB, Davis K, Ahuja N. (2020)

Results of COVID-minimal Surgical Pathway During Surge-phase of COVID-19 Pandemic.

Annals of Surgery, 272(6):e316-e320.

[Read More](#)

Liu YL, Ren J, Yuan JP, Zhang ZJ, Guo WY, Guan Y, Moeckel G, Ahuja N, Fu T (2020).

Postoperative Onset and Detection of SARS-CoV-2 in Surgically Resected Specimens From Gastrointestinal Cancer Patients With Pre/Asymptomatic COVID-19.

Annals of Surgery, 272(6):e321-e328.

[Read More](#)

Funding and Award Opportunities

Basser Center For BRCA External Research Grant Program - Basser Innovation Award

Research grant applications in basic science, prevention, early detection, or targeted therapeutics and relevant to the study of BRCA1/2 will be considered.

Letter of Intent Due: December 21, 2020

[Read More](#)

Health and Environmental Sciences Institute (HESI) THRIVE

THRIVE fills a critical gap in funding for foundational research in support of future protective therapies, mitigation strategies and a next generation of therapy and therapy-support that will enhance the ability for cancer patients and survivors to THRIVE.

Letter of Intent Due: December 31, 2020

[Read More](#)

2021 K12 Immuno-Oncology Training Program (IOTP) Scholar Awards

We are pleased to solicit applications for the Yale Cancer Center (YCC) K12 Calabresi Immuno-Oncology Training Program (IOTP) Scholar Award for junior faculty to enhance research skills beyond the training provided during graduate and postgraduate training.

Application Deadline: January 4, 2021

[IOTP Award Instructions](#)

[IOTP Award Application](#)

NCI Research Specialist Awards

- Core-Based Award: **Application Deadline** - January 4, 2021
- This FOA invites grant applications in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists.

Laboratory-Based Award: **Application Deadline** - January 4, 2021

This FOA invites grant applications in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists.

[Read More](#)

Yale Head and Neck SPORE (YHN-SPORE) Career Enhancement Program

The CEP of the Yale Head and Neck SPORE has been established to educate the next generation of investigators committed to translational research in head and neck cancer. The CEP will provide support to promising junior investigators and/or establish investigators who have not previously conducted head and neck cancer focused research.

Application Deadline: January 5, 2021

Read More

Yale Head and Neck SPORE (YHN-SPORE) Developmental Research Program

The Yale Head and Neck SPORE's DRP provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full YHN-SPORE project or to generate preliminary data or evidence of collaboration for other new NIH grant applications.

Application Deadline: January 5, 2021

Read More

NCI Cancer Clinical Investigator Team Leadership Award (CCITLA) P30 Administrative Supplement for Fiscal Year (FY) 2021

This award recognizes and supports outstanding clinical investigators who enable their cancer center's NCI-funded clinical trials enterprise.

Application Deadline: January 11, 2021

Read More

The **American Head and Neck Society** will sponsor nine research grants for 2021 which are available through American Academy of Otolaryngology CORE.

- AHNS/AAO-HNSF Young Investigator Combined Award
- AHNS/AAO-HNSF Translational Innovator Award
- AHNS Pilot Grant
- AHNS Ballantyne Resident Research Pilot Grant
- AHNS Endocrine Surgery Section Eisai Research Award
- AHNS Endocrine Surgery Section Stryker Research Grant
- AHNS Presidential Request for Application Pilot Award on Mucosal Head and Neck Cancer Research
- AHNS Presidential Request for Application Pilot Award on Salivary Gland Cancer Research
- AHNS Presidential Request for Application Pilot Award on Basic and Translational Research

Full Application Deadline: January 15, 2021

Read More

Collaborative Approaches to Engineer Biology for Cancer Applications (U01)

This FOA invites applications to develop and apply innovative synthetic biology approaches to address challenges across the spectrum of cancer research.

Application Deadline: January 15, 2021

Read More

RFI Regarding Opportunities for New National Programs at the NCI's Frederick National Laboratory for Cancer Research

NCI's Frederick National Laboratory for Cancer Research

The purpose of this RFI is to seek input from members of the cancer research community on the most important needs and promising opportunities in cancer research that are difficult to address on an individual scale.

Submission Deadline: January 18, 2021

Read More

NCCN Request for Proposals (RFP): Phase I/II Clinical and Correlative/Preclinical Trials of Decitabine and Cedazuridine for Hematologic Malignancies and Solid Tumors

This RFP, made possible by a research grant from Taiho Oncology, Inc., is to support NCCN Member Institution faculty for the performance of clinical and correlative studies of decitabine and cedazuridine (DEC-C) in the treatment of hematologic malignancies and solid tumors.

Application Deadline: January 19, 2021

Read More

Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (U01)

The overarching goal of this FOA is to expand comparative simulation modeling approaches developed by CISNET to new cancer organ sites beyond the sites which have been previously funded (breast, colorectal, prostate, lung, esophageal, and cervical) under CISNET.

Application Deadline: January 20, 2021

Read More

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50)

Through this FOA, the NCI and National Institute of Dental and Craniofacial Research (NIDCR) invite applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE)

Application Deadline: January 25, 2021

Read More

Cancer Research Education Grants Program

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of the NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.

- Curriculum or Methods Development (R25 Clinical Trial Not Allowed) **Read More**
- Courses for Skills Development (R25 Clinical Trial Not Allowed)

Read More

- Research Experiences (R25 Clinical Trial Not Allowed) **Read More**

Due Dates: January 25, 2021

New Cohorts for Environmental Exposures and Cancer Risk (CEECR) (UG3/UH3/U24)

Through this FOA, the NCI and NIEHS invite applications to support innovative scientific research in new prospective cohorts that addresses knowledge gaps in cancer etiology and carcinogenesis processes with a focus on environmental exposures.

Application Deadline: January 29, 2021

Read More

DeLuca Awards

The DeLuca Center for Innovation in Hematology Research was formed thanks to a generous donation by the Fredrick A. DeLuca Foundation. Each year a total of 5 Pilot Awards and 1 Career Development Award will be awarded to investigators who are participating in hematologic based research.

Pilot Award: intended to support collaborative hematology based research.

Application Deadline: February 1, 2021

Read More

Career Development Award: intended to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes.

Letter of Intent Due: March 1, 2021

Read More

Utilizing In Vitro Functional Genomics Advances for Gene-Environment (G x E) Discovery and Validation (R01)

The purpose of this FOA is to solicit applications that fully integrate recent innovative advances of in vitro functional genomics tools/technologies and approaches for environmental health and toxicology research. The overall goal of this NIEHS led initiative is to generate proof-of-principle studies incorporating these new in vitro approaches, together with well characterized exposures, to further our understanding of gene-environment (G x E) interactions in complex human disorders.

Application Deadline: February 1, 2021

Read More

2021-2023 Clinical Investigator Award for Under-Represented Black, Indigenous, and People of Color (BIPOC) Surgeons

This award is part of the SSO Diversity and Inclusion Advisory Board's work to ensure inclusion of the brightest minds and keenest talents in surgical oncology research. Applications are reviewed and selected by members of the SSO Research Committee.

Application Deadline: February 8, 2021

Read More

Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01)

The purpose of this FOA is to bring a highly sensitive imaging technology capable of detecting very small (1-3 mm³) tumors *in vivo* to clinical utility.

Application Deadline: February 10, 2021

Read More

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3)

Through these FOAs, the NCI invites applications to support the validation of high quality markers for clinical studies in cancer.

validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control.

Application Deadline: February 18, 2021

Read More

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research.

Application Deadline: February 22, 2021

Read More

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)

This FOA invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research.

Application Deadline: February 22, 2021

Read More

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care.

Application Deadline: February 22, 2021

Read More

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care.

Application Deadline: February 22, 2021

Read More

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions.

Application Deadline: February 26, 2021

Read More

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers.

Application Deadline: February 26, 2021

Read More

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions.

Application Deadline: February 26, 2021

Read More

JH Milestone Fund 2021

This FOA supports early stage investigators and innovative research and education in thrombosis, thrombolysis and hemostasis. Proposals may focus on any aspect of thrombosis, thrombolysis and hemostasis – including biochemistry, genetics, clinical evaluation and testing, quality improvement and treatment. Please contact **Richard Carr** for more information.

Letter of Intent Due: March 1, 2021

Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in Rural Populations (R01)

The purpose of this FOA is to solicit applications to develop, adapt, and test individual-, community- or multilevel interventions to address modifiable risk factors for cancer in rural populations.

Application Deadline: March 15, 2021

Read More

Cellular Cancer Biology Imaging Research (CCBIR) Program (U54)

The NCI invites applications for Cellular Cancer Biology Imaging Research (CCBIR) Centers. The Centers will develop and test enabling imaging technologies at the cellular and organ scales driven by specific fundamental questions in cancer biology. The overall purpose of the CCBIR initiative is to facilitate innovation in advanced imaging technologies that could be applied to fundamental basic and pre-clinical research problems in cancer biology.

Application Deadline: March 18, 2021

Read More

Cancer Grand Challenges Program

The NCI and Cancer Research UK (CRUK) are partnering to fund the Cancer Grand Challenges program. Cancer Grand Challenges will fund novel ideas by multidisciplinary research teams from around the world that offer the potential to advance bold cancer research and improve outcomes for people affected by cancer. These nine challenges are aimed at solving complex problems in cancer research, which, if solved, could have a transformative impact towards progress.

Application Deadline: April 22, 2021

[Read More](#)